Top story: EpiVax says Novozymes collaboration has $3bn potential
In-PharmaTechnologist.com, February 2013
Novozymes and EpiVax team up to fight autoimmune diseases
Genetic Engineering & Biotechlogy News, February 2013
The need for improved half-life extension technologies
Drug Discovery News, January 2013
Allowing manufacturers to modify protein or peptide half-life to suit the requirements of specific medical conditions
ONdrugDelivery, December 2012
Half-life extension technology - Building Better Bioavailability
Drug Discovery and Development, November 2012
Half-life extension technology - Recombinant human albumin: Delivering the future of Type 2 Diabetes medication
Drug Development and Delivery, October 2012
Recombinant albumin provides a flexible platform to deliver longer lasting drugs
Nature Biotechnology Volume 30, Number 6 June 2012
Tailoring drug half-life for enhanced delivery
Manufacturing Chemist, June 2012
Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor Nature Communications Volume: 3, Article number: 610, January 2012
Bio-platforms of the future: New technologies will add flexibility, extend circulatory half-life
Contract Pharma, November/December 2010
Flight of fusion: Dave Mead at Novozymes Biopharma explains how extended circulatory half-life and the bioavailability of biological drugs can be acheived with albumin fusion technology
EBR Drug Discovery, June 2009
Next Generation Pharmaceutical online editorial
Dr Dave Mead and Dr Ruth McDermott, 2008